Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Bone Marrow Cells in Chronic Coronary Occlusion
NCT02022514Phase 3Completed
- Start
- Nov 2013
- Primary completion
- Aug 2023
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of autologous bone marrow-derived mononuclear cell in Chronic coronary occlusion (CTO) and ventricular dysfunction (2 arms). Primary endpoint: Left Ventricular Ejection Fraction at 6 months. Started Nov 2013; status: completed.
02
Drugs
autologous bone marrow-derived mononuclear cell
03
Conditions
Chronic coronary occlusion (CTO)ventricular dysfunction
Beyond the preview
Go deeper on NCT02022514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02022514.